The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr Lena Landstedt-Hallin has been working as a clinician with focus on diabetology during the main part of her professional life. She studied medicine at the Karolinska Institute (KI), Stockholm and received her MD in 1984. While studying for a PhD at KI, presenting her thesis in 2000, she also completed residencies in both Endocrinology/Diabetology and Internal Medicine. At Danderyd University Hospital, where she worked for over thirty years, she has acted as an investigator in local and multicentre studies, tutored PhD students and also held administrative positions. Her latest published research has been RWD data regarding insulin degludec. In 2013 she received the award “Clinical diabetologist of the year” from her peers in the Swedish Association for Diabetologists (SFD). She is now semi-retired but continues to work clinically 1-2 days per week at a small hospital I Norrtälje, north of Stockholm, coaching people with type 1 diabetes.
University of Minnesota, Minneapolis, USA
Richard M. Bergenstal, MD, is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. He is Clinical Professor in the Department of Medicine at the University of Minnesota and served as President, Science & Medicine of the American Diabetes Association in 2010. In 2007, Dr. Bergenstal was named the ADA’s Outstanding Physician Clinician of the Year and in 2010 he was awarded the Banting Medal for Service for outstanding leadership and service to the American Diabetes Association. Dr. Bergenstal received his MD and endocrine training from the University of Chicago where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983. His clinical research has focused on glucose control and diabetes complications and he has served as a Principal Investigator of five NIH trials: the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes and the Action to Control Cardiovascular Risks in Diabetes (ACCORD) study and the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) study in type 2 diabetes and 2 technology focused NIH grants (Hygieia – study of insulin dose advisor system, Artificial Pancreas grant to study next generation automated insulin delivery systems).
Dr. Bergenstal’ s clinical efforts have been directed toward improving systems of care for patients with diabetes by translating new research findings into practice. He studies the effective utilization of insulin therapy and standardization glucose monitoring (SMBG and CGM) to improve glucose control and clinical outcomes. He teaches nationally and internationally on the importance of patient‐centered team care, has been listed in Best Doctors in America since it began in 1992, has published over 250 peer reviewed scientific articles in diabetes.
University of Gothenburg, Kungsbacka, Sweden
Peter Adolfsson, MD PhD, Senior consultant at the Department of pediatrics, The hospital of Halland – Kungsbacka, Sweden. Institution of clinical sciences, Sahlgrenska Academy at the University of Gothenburg, Sweden.
Peter completed his medical education at Sahlgrenska Academy, University of Gothenburg and later specialized in pediatrics and sports medicine. Peter has previously been active as physician for the Swedish women's national football team for 9 years and his interest in sports has later also been reflected in his research within diabetes. Moreover, his research covers aspects of the use of technology in diabetes care including smart pens, continuous glucose monitoring, and insulin pumps. Peter was one of the founders of Diasend and a board member of this company until 2016.
During the evolution of technology within diabetes care, Peter has created pedagogical guides on how to implement both isCGM and rtCGM in clinical practice and is one of the main responsibles of two national courses in insulin pump technology and the use of advanced technology in diabetes care.
Örebro University, Örebro, Sweden
Johan Jendle is professor in medicine and teaching chair at the faculty of Medical Sciences at Örebro University, Sweden. He is the director of the Diabetes, Endocrinology and Metabolism Research Centre at Örebro University.
He received his medical degree from the University of Linköping, Sweden in 1991 and senior consultant in both endocrinology and internal medicine.
He has authored more than 100 papers published in peer-reviewed journals. Special areas of interest include type 1 diabetes and physical exercise, endurance sports, skydiving and SCUBA-diving.
His research is currently focused health economic aspects of diabetes (T1D and T2D), e-health and predictions using AI, smart insulin pumps and pens as well as novel treatment of obesity and diabetes.
Prof Jendle is a member of the study group the European Association for the Study of Diabetes eye complications (EASDec), the study group of physical activities the European Association for the Study of Diabetes (ExPAS).